BRKR Bruker Corporation

Bruker BioSciences Corporation (Nasdaq: BRKR) today announced that it will join other leading life sciences companies in presenting at the UBS Global Life Sciences Conference taking place September 26-29 in New York. Bruker BioSciences Corporation's President and CEO, Frank Laukien, will present an overview of the Company, including an update on recent developments, recently-announced product innovations, and expectations. He will be accompanied by Chief Financial Officer William J. Knight. Dr. Laukien's presentation will be webcast live at 11:30 AM Eastern Time (8:30 AM Pacific Time) on Wednesday, September 28, 2005 from the Grand Hyatt Hotel in New York. The webcast can be accessed on Bruker BioSciences' website at www.bruker-biosciences.com with playback available until October 28. ABOUT BRUKER BIOSCIENCES Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.